99 related articles for article (PubMed ID: 16094623)
1. Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease.
Tanus-Santos JE; Gerlach RF
Int J Cancer; 2006 Feb; 118(3):789; author reply 790. PubMed ID: 16094623
[No Abstract] [Full Text] [Related]
2. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.
Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
Int J Cancer; 2005 Sep; 116(3):422-7. PubMed ID: 15818624
[TBL] [Abstract][Full Text] [Related]
4. Analysis of preoperative serum levels of MMP1, -2, and -9 in patients with site-specific head and neck squamous cell cancer.
Kalfert D; Ludvikova M; Topolcan O; Windrichova J; Malirova E; Pesta M; Celakovsky P
Anticancer Res; 2014 Dec; 34(12):7431-41. PubMed ID: 25503184
[TBL] [Abstract][Full Text] [Related]
5. Serum Level of Matrix Metalloproteinase-9 in Patients with Head and Neck Squamous Cell Carcinoma.
Stanciu AE; Zamfir-Chiru-Anton A; Stanciu MM; Popescu CR; Gheorghe DC
Clin Lab; 2016 Aug; 62(8):1569-1574. PubMed ID: 28164611
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
Riedel F; Götte K; Schwalb J; Hörmann K
Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells as biomarkers of head and neck squamous cell carcinoma: an updated view.
Mangano A; Mangano A; Lianos GD; Levrini L; Picone M; Boni L; Dionigi G
Future Oncol; 2015; 11(13):1851-3. PubMed ID: 26161921
[No Abstract] [Full Text] [Related]
8. A liquid biopsy for head and neck cancers.
Schmidt H; Kulasinghe A; Perry C; Nelson C; Punyadeera C
Expert Rev Mol Diagn; 2016; 16(2):165-72. PubMed ID: 26631411
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
Economopoulou P; Kotsantis I; Kyrodimos E; Lianidou ES; Psyrri A
Oral Oncol; 2017 Nov; 74():83-89. PubMed ID: 29103757
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating tumour cells with the CellSearch system in patients with advanced-stage head and neck cancer: preliminary results.
He S; Li P; He S; Long T; Zhang N; Fang J; Yu Z
J Laryngol Otol; 2013 Aug; 127(8):788-93. PubMed ID: 23835309
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
[TBL] [Abstract][Full Text] [Related]
13. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.
Mannello F
Cancer; 2003 Jan; 97(1):201-3; author reply 203-4. PubMed ID: 12491521
[No Abstract] [Full Text] [Related]
14. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
15. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer.
Chang PY; Kuo YB; Wu TL; Liao CT; Sun YC; Yen TC; Chan EC
Clin Chem Lab Med; 2013 Jun; 51(6):1291-300. PubMed ID: 23154424
[TBL] [Abstract][Full Text] [Related]
16. Circulating markers in squamous cell carcinoma of the head and neck: a review.
Rassekh CH; Johnson JT; Eibling DE
Eur J Cancer B Oral Oncol; 1994 Jan; 30B(1):23-8. PubMed ID: 9135969
[TBL] [Abstract][Full Text] [Related]
17. An update: circulating tumor cells in head and neck cancer.
Kulasinghe A; Hughes BGM; Kenny L; Punyadeera C
Expert Rev Mol Diagn; 2019 Dec; 19(12):1109-1115. PubMed ID: 31680565
[No Abstract] [Full Text] [Related]
18. Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas.
Nunes DN; Kowalski LP; Simpson AJ
Int J Cancer; 2001 Apr; 92(2):214-9. PubMed ID: 11291048
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of head and neck tumor markers].
Gascón Vilaplana P
Med Clin (Barc); 2007 Dec; 129(20):775-6. PubMed ID: 18093479
[No Abstract] [Full Text] [Related]
20. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
